Reuters logo
BRIEF-Gensight Biologics cash and cash equivalents as of March 31, 2017 down at 48.8 million euros
April 26, 2017 / 5:56 AM / 6 months ago

BRIEF-Gensight Biologics cash and cash equivalents as of March 31, 2017 down at 48.8 million euros

April 26 (Reuters) - Gensight Biologics SA:

* Gensight Biologics’ cash and cash equivalents amounted to 48.8 million euros ($53.41 million) as of March 31, 2017, compared to 54.0 million euros as of Dec. 31, 2016 Source text for Eikon: Further company coverage: ($1 = 0.9137 euros) (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below